Junyuan Jerry Wang - 09 Apr 2024 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Reporting relationship: CEO, ANHEART THERAPEUTICS LTD., Director
Issuer ticker: NUVB
Reported as of: 09 Apr 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Apr 2024, 18:30:40 UTC
Next SEC filing: 05 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Ron Metzger, Attorney-in-Fact

Key filing fact

Junyuan Jerry Wang filed Form 4 for Nuvation Bio Inc. (NUVB) on 11 Apr 2024.

Key facts

This page summarizes Junyuan Jerry Wang's Form 4 filing for Nuvation Bio Inc. (NUVB).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Apr 2024, 18:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVB transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +1,378,989
Change %
Price: $0.000000
Shares after: 1,378,989
Date: 09 Apr 2024
Ownership: Direct
Footnotes: F1, F2, F3

NUVB transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +550,758
Change %
Price: $0.000000
Shares after: 550,758
Date: 09 Apr 2024
Ownership: By LLC
Footnotes: F1, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NUVB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +486,669
Change %
Price: $0.000000
Shares after: 486,669
Date: 09 Apr 2024
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 486,669
Exercise price: $0.6800
Footnotes: F6, F7

NUVB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +388,299
Change %
Price: $0.000000
Shares after: 388,299
Date: 09 Apr 2024
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 388,299
Exercise price: $0.6800
Footnotes: F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

Received pursuant to the Agreement and Plan of Merger and Reorganization, dated as of March 24, 2024, by and among Nuvation Bio Inc. (the "Issuer"), AnHeart Therapeutics Ltd. ("AnHeart"), Artemis Merger Sub I, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub I"), and Artemis Merger Sub II, Ltd., a wholly owned subsidiary of the Issuer ("Merger Sub II"), whereby Merger Sub I merged with and into AnHeart, with AnHeart surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "First Merger"). Immediately following the First Merger, AnHeart, as the surviving company of the First Merger, merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of the Issuer (the "Second Merger" and, collectively with the First Merger, as appropriate, the "Merger").

Footnote F2

Received in exchange for 1,920,000 ordinary shares of AnHeart in connection with the Merger (as described in footnote 1) on April 9, 2024.

Footnote F3

Includes 552,852 shares subject to restricted stock units ("RSUs") received in exchange for 315,000 RSUs of AnHeart, which will vest based upon the satisfaction of performance-based criteria.

Footnote F4

Received in exchange for 1,280,000 ordinary shares of AnHeart in connection with the Merger (as described in Footnote 1 ) on April 9, 2024.

Footnote F5

Shares are held directly by WangWang, LLC, of which the Reporting Person is Manager.

Footnote F6

Received in exchange for an option to purchase 277,290 ordinary shares of AnHeart at an exercise price of $1.185 per share in connection with the Merger (as described in footnote 1) on April 9, 2024.

Footnote F7

Option vests as to 25% on the first anniversary of 1/1/2021, and the remainder of the shares will vest in 12 successive equal quarterly installments thereafter, subject to Reporting Person's continuous service on each such vesting date.

Footnote F8

Received in exchange for an option to purchase 221,242 ordinary shares of AnHeart at an exercise price of $1.185 per share in connection with the Merger (as described in footnote 1) on April 9, 2024.

Footnote F9

Option vests as to 25% on the first anniversary of 1/1/2022, and the remainder of the shares will vest in 12 successive equal quarterly installments thereafter, subject to Reporting Person's continuous service on each such vesting date.